For­mer No­var­tis drug for ul­tra-rare dis­ease gets speedy FDA re­view

Three years af­ter pay­ing a mod­est $20 mil­lion up­front to grab a late-stage rare dis­ease drug from No­var­tis, Pharm­ing has lined up a pri­or­i­ty re­view at the FDA.

Known at the time as CDZ173, le­niolis­ib be­longs to the PI3Kẟ (phos­pho­inosi­tide 3-ki­nase delta) in­hibitor class, which is best known for can­cer ap­pli­ca­tions. But No­var­tis took a dif­fer­ent path, test­ing it for an im­mun­od­e­fi­cien­cy dis­ease called ac­ti­vat­ed phos­pho­inosi­tide 3-ki­nase delta syn­drome, or APDS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER